GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (OSTO:XSPRAY) » Definitions » Debt-to-Equity

XSpray Pharma AB (OSTO:XSPRAY) Debt-to-Equity : 0.06 (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is XSpray Pharma AB Debt-to-Equity?

XSpray Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr5.05 Mil. XSpray Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr28.56 Mil. XSpray Pharma AB's Total Stockholders Equity for the quarter that ended in Sep. 2024 was kr585.59 Mil. XSpray Pharma AB's debt to equity for the quarter that ended in Sep. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for XSpray Pharma AB's Debt-to-Equity or its related term are showing as below:

OSTO:XSPRAY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.01   Max: 0.06
Current: 0.06

During the past 9 years, the highest Debt-to-Equity Ratio of XSpray Pharma AB was 0.06. The lowest was 0.00. And the median was 0.01.

OSTO:XSPRAY's Debt-to-Equity is ranked better than
68.49% of 1025 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:XSPRAY: 0.06

XSpray Pharma AB Debt-to-Equity Historical Data

The historical data trend for XSpray Pharma AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Debt-to-Equity Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.01 0.01 0.01 - 0.05

XSpray Pharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.05 0.06 0.05 0.06

Competitive Comparison of XSpray Pharma AB's Debt-to-Equity

For the Biotechnology subindustry, XSpray Pharma AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XSpray Pharma AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's Debt-to-Equity falls into.



XSpray Pharma AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

XSpray Pharma AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

XSpray Pharma AB's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XSpray Pharma AB  (OSTO:XSPRAY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


XSpray Pharma AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


XSpray Pharma AB Business Description

Traded in Other Exchanges
Address
Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and XS00Y.

XSpray Pharma AB Headlines

No Headlines